These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 15710671

  • 1. Effect of bovine lactoferrin on the MICs of ampicillin/sulbactam (UNASYN), amoxicillin/clavulanic acid (Augmentin), ticarcillin clavulanate (Timentin), and piperacillin-tazobactam (ZOSYN), against clinical and environmental isolates of motile Aeromonas.
    WaKabongo M, Stucki ZN, Torbert DP, Olweny J.
    J Am Osteopath Assoc; 2005 Jan; 105(1):25-6. PubMed ID: 15710671
    [No Abstract] [Full Text] [Related]

  • 2. Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone.
    Pankuch GA, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2905-7. PubMed ID: 7695281
    [Abstract] [Full Text] [Related]

  • 3. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS, Tosin I, Sejas L, Miranda E.
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [Abstract] [Full Text] [Related]

  • 4. Piperacillin tazobactam compared with co-amoxiclav, ampicillin plus sulbactam and timentin against beta-lactamase-producing clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca.
    Traub WH, Leonhard B.
    Chemotherapy; 1995 Feb; 41(5):345-52. PubMed ID: 8521736
    [Abstract] [Full Text] [Related]

  • 5. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S, Hanaki H, Nagayama A.
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [Abstract] [Full Text] [Related]

  • 6. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
    Gatermann S, Marre R.
    Infection; 1991 Apr; 19(2):106-9. PubMed ID: 1646771
    [Abstract] [Full Text] [Related]

  • 7. [The effectiveness of so-called potentiated penicillins (augmentin and tazobactam) in vitro].
    Blahová J, Hupková M, Krcméry V.
    Cas Lek Cesk; 1995 Sep 06; 134(17):558-61. PubMed ID: 7553760
    [Abstract] [Full Text] [Related]

  • 8. Beta-lactamase inhibitors and Acinetobacter spp.
    Eng RH, Smith SM, Cherubin CE.
    J Antimicrob Chemother; 1990 Sep 06; 26(3):449-51. PubMed ID: 2172200
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa.
    Klepser ME, Marangos MN, Zhu Z, Nicolau DP, Quintiliani R, Nightingale CH.
    Antimicrob Agents Chemother; 1997 Feb 06; 41(2):435-9. PubMed ID: 9021203
    [Abstract] [Full Text] [Related]

  • 10. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.
    Fass RJ, Prior RB.
    Antimicrob Agents Chemother; 1989 Aug 06; 33(8):1268-74. PubMed ID: 2552904
    [Abstract] [Full Text] [Related]

  • 11. In vitro activity of YTR 830.
    Jacobs MR, Aronoff SC, Appelbaum PC, Yamabe S.
    J Chemother; 1989 Jun 06; 1(3):151-4. PubMed ID: 2552029
    [Abstract] [Full Text] [Related]

  • 12. [Bactericidal activity of combinations of ticarcillin-clavulanic acid or other beta-lactams (amoxicillin, piperacillin-tazobactam, ticarcillin) with gentamicin against Enterococcus faecalis and E. faecium].
    Leclercq R, Duval J.
    Pathol Biol (Paris); 1995 Apr 06; 43(4):245-52. PubMed ID: 7567109
    [Abstract] [Full Text] [Related]

  • 13. Use of beta-lactam/beta-lactamase-inhibitor combinations as antimycobacterial agents.
    Prabhakaran K, Harris EB, Randhawa B, Adams LB, Williams DL, Hastings RC.
    Microbios; 1993 Apr 06; 76(309):251-61. PubMed ID: 8302203
    [Abstract] [Full Text] [Related]

  • 14. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
    Kuck NA, Jacobus NV, Petersen PJ, Weiss WJ, Testa RT.
    Antimicrob Agents Chemother; 1989 Nov 06; 33(11):1964-9. PubMed ID: 2558615
    [Abstract] [Full Text] [Related]

  • 15. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
    Higgins PG, Wisplinghoff H, Stefanik D, Seifert H.
    Antimicrob Agents Chemother; 2004 May 06; 48(5):1586-92. PubMed ID: 15105109
    [Abstract] [Full Text] [Related]

  • 16. Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations.
    Thomson KS, Weber DA, Sanders CC, Sanders WE.
    Antimicrob Agents Chemother; 1990 Apr 06; 34(4):622-7. PubMed ID: 2344169
    [Abstract] [Full Text] [Related]

  • 17. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanic acid and sulbactam combined with ampicillin and piperacillin against beta-lactamase producing anaerobic bacteria.
    Nord CE.
    J Chemother; 1989 Jul 06; 1(4 Suppl):273-5. PubMed ID: 16312398
    [No Abstract] [Full Text] [Related]

  • 18. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
    Mohanty S, Singhal R, Sood S, Dhawan B, Das BK, Kapil A.
    Indian J Med Res; 2005 Nov 06; 122(5):425-8. PubMed ID: 16456257
    [Abstract] [Full Text] [Related]

  • 19. In vitro activities of antibacterial agents against clinical isolates of Escherichia coli and Klebsiella species from intensive care units.
    Gill CJ, Ponticas S, Shungu DL, Guerriero S.
    Clin Ther; 1991 Nov 06; 13(1):25-37. PubMed ID: 2029725
    [Abstract] [Full Text] [Related]

  • 20. Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae.
    Pfaller M, Barry A, Fuchs P, Gerlach E, Hardy D, McLaughlin J.
    Eur J Clin Microbiol Infect Dis; 1993 Mar 06; 12(3):200-5. PubMed ID: 8389705
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.